purine/stroke

Lyen an sove nan clipboard la

Chwazi kalite sòt

9 rezilta yo

Purine receptor inhibition as a therapeutic strategy in spinal cord and brain

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

FIELD OF THE INVENTION The present invention is directed to inhibition of purine receptors as a therapeutic strategy in spinal cord and brain injury. BACKGROUND OF THE INVENTION Acute spinal injury is a major public health problem. Spinal cord injuries resulting in paralysis or other severe

Systemic purine administration: modulating axonal outgrowth of central nervous system neurons

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

FIELD OF THE INVENTION The invention relates to methods and compositions for modulating the axonal outgrowth of central nervous system neurons. In particular, the invention provides means of internalized purine administration. BACKGROUND OF THE INVENTION After early childhood, injury to the central

Purine derivatives

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

FIELD OF INVENTION The present invention relates to new 2,6,9-substituted purine derivatives and their biological applications. In particular, the invention relates to purine derivatives having antiproliferative properties which are useful in the treatment of proliferative disorders such as cancer,

Purine derivatives

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Purine derivatives

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

RELATED APPLICATIONS This application is a continuation of PCT/GB2003/003554, filed on Aug. 13, 2003, which claims priority to GB 0219054.4 filed on Aug. 15, 2002. The entire contents of both of these applications are hereby incorporated herein by reference. FIELD OF INVENTION The present invention

Trisubstituted purine derivatives

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Purine derivatives as A3 and A1 adenosine receptor agonists

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

FIELD OF THE INVENTION This invention pertains to A.sub.3 and A.sub.1 adenosine receptor agonists, pharmaceutical compositions comprising such agonists, and a method of use thereof, for example, in treating various medical disorders. BACKGROUND OF THE INVENTION Extracellular adenosine acts as a

Purine derivatives as A.sub.3 adenosine receptor-selective agonists

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

BACKGROUND OF THE INVENTION Extracellular adenosine acts as a local modulator at four subtypes of adenosine receptors, namely, A.sub.1, A.sub.2A, A.sub.2B, and A.sub.3, which are involved in numerous physiological and pathophysiological processes. Fredholm et al., Pharmacol. Rev. 2001; 53:527-52.

Methods for treatment using small molecule potassium-sparing diuretics and natriuretics

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

FIELD This relates to the field of small molecule PNPase substrates and inhibitors as well as potassium-sparing diuretics and natriuretics and methods of their use. BACKGROUND With the notable exceptions of mineralocorticoid antagonists and epithelial sodium channel (ENaC) inhibitors, most

Antre nan paj
facebook nou an

Herbal & Natural Medicine

Baz done ki pi konplè remèd fèy medsin te apiye nan syans

Travay nan 55 lang
Geri èrbal te apiye nan syans
Remèd fèy rekonesans pa imaj
Kat entèaktif GPS - tag zèb sou kote (vini byento)
Li piblikasyon syantifik ki gen rapò ak rechèch ou an
Search remèd fèy medsin pa efè yo
Izeganize enterè ou yo ak rete kanpe fè dat ak rechèch la nouvèl, esè klinik ak rive

Tape yon sentòm oswa yon maladi epi li sou remèd fèy ki ta ka ede, tape yon zèb ak wè maladi ak sentòm li itilize kont.
* Tout enfòmasyon baze sou rechèch syantifik pibliye